Haroun Gajraj: Polidocanol or STS – Choosing the Right Sclerosant
Haroun Gajraj, Phlebologist and Board Member of the British Association of Sclerotherapists, shared a post on LinkedIn:
“The Best Sclerosant for Leg Spider Veins: Polidocanol or STS?
Every phlebologist has this debate at some point.
Here’s my opinion: neither is proven to be categorically better.
The trial everyone points to (EASI) compared one specific polidocanol regimen against one specific STS regimen, not the drugs at equivalent strength.
Patients were more satisfied with the polidocanol arm, but that’s a regimen finding, not proof of superiority.
The older comparative studies don’t settle it either, and the lab data on platelets and clotting is useful mechanistic background, not a real-world complication-rate comparison between the two.
So how do you actually choose?
Patient comfort, prior individual response, and your own consistent technique are all important deciding factors, on the evidence we currently have.
What sclerosant do you use?
I look at the evidence and I spell it all out in my latest blog post …”
Other posts featuring Haroun Gajraj on Hemostasis Today.
-
Oct 23, 2026, 17:45Lucy Brook: Had the Privilege of Attending the Blood 2026 Conference with New Zealand Blood Service
-
Oct 23, 2026, 16:05Platelet Secretion Defects and Their Role in the Diagnosis of Bleeding Disorders
-
Oct 23, 2026, 16:00Hemophilia Alliance team in New Orleans at the ATHN Data Summit
-
Oct 23, 2026, 15:49Brian Sapp: Why Exact Calf Vein Naming Is Critical for DVT Diagnosis?
-
Oct 23, 2026, 15:33Smitirupa Mishra: A Systematic Approach to Bone Marrow Examination
-
Oct 23, 2026, 15:29José Antonio García Erce: Preoperative Anemia Emerges as a Modifiable Surgical Risk in New POWER Study
-
Oct 23, 2026, 15:13Reza Shojaei: Manufactured Red Blood Cells vs Blood Donation
-
Oct 23, 2026, 14:29Jean Jacques Kiladjian: International Scientific Exchange at IHCAMS in Tianjin
-
Oct 23, 2026, 14:11Aravind Palraj: The Prolonged aPTT Puzzle in SLE